Research ArticleToxicology
Multiple Compound-Related Adverse Properties Contribute to Liver Injury Caused by Endothelin Receptor Antagonists
J. Gerry Kenna, Simone H. Stahl, Julie A. Eakins, Alison J. Foster, Linda C. Andersson, Jonas Bergare, Martin Billger, Marie Elebring, Charles S. Elmore and Richard A. Thompson
Journal of Pharmacology and Experimental Therapeutics February 2015, 352 (2) 281-290; DOI: https://doi.org/10.1124/jpet.114.220491
J. Gerry Kenna
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Simone H. Stahl
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Julie A. Eakins
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Alison J. Foster
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Linda C. Andersson
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Jonas Bergare
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Martin Billger
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Marie Elebring
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Charles S. Elmore
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
Richard A. Thompson
Drug Safety Consultant, Macclesfield, Cheshire, United Kingdom (J.G.K.); DMPK (S.H.S.), Discovery Safety (J.A.E.), and Translational Safety (A.J.F.), Drug Safety and Metabolism, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, United Kingdom; DMPK (L.C.A., J.B., C.S.E.), Regulatory Safety (M.B.), Drug Safety and Metabolism, AstraZeneca R&D Mölndal, Mölndal, Sweden; and DMPK, Cardiovascular and Metabolic Diseases (M.E.), and Respiratory, Inflammation, and Autoimmunity (R.A.T.), iMED AstraZeneca R&D Mölndal, Mölndal, Sweden
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleToxicology
Liver Injury Due to Endothelin Receptor Antagonists
J. Gerry Kenna, Simone H. Stahl, Julie A. Eakins, Alison J. Foster, Linda C. Andersson, Jonas Bergare, Martin Billger, Marie Elebring, Charles S. Elmore and Richard A. Thompson
Journal of Pharmacology and Experimental Therapeutics February 1, 2015, 352 (2) 281-290; DOI: https://doi.org/10.1124/jpet.114.220491
Research ArticleToxicology
Liver Injury Due to Endothelin Receptor Antagonists
J. Gerry Kenna, Simone H. Stahl, Julie A. Eakins, Alison J. Foster, Linda C. Andersson, Jonas Bergare, Martin Billger, Marie Elebring, Charles S. Elmore and Richard A. Thompson
Journal of Pharmacology and Experimental Therapeutics February 1, 2015, 352 (2) 281-290; DOI: https://doi.org/10.1124/jpet.114.220491
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement